查看購物車
  • Simplified Chinese
  • Japanese
  • Korean
近視管理市場（2025）
市場調查報告書
商品編碼
1907771

近視管理市場（2025）

2025 Myopia Management Survey Report
出版日期: | 出版商: Market Scope, LLC | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

Market Scope 的 "近視管理市場（2025）" 報告對美國兒童近視管理的現狀進行了全面的提供者層面分析。報告考察了患者群體、治療組合、經濟狀況、未滿足的需求以及隨著新型療法進入市場可能出現的臨床行為變化。

這項調查於 2025 年 8 月至 9 月進行，收集了 150 位美國驗光師和眼科醫生的見解，其中包括積極治療近視的普通眼科醫生和兒科眼科醫生。受訪者選自 Market Scope 的自註冊醫療服務提供者社區，代表了在近視管理方面擁有直接經驗的真實決策者。

本報告透過分析受訪者層面的匿名調查數據，並排除市場整體估算，提供結構化的總結分析，清楚地闡述了醫療服務提供者的思考、處方、定價和規劃。

目錄：

"近視管理市場（2025）報告" 詳細分析了醫療服務提供者接診的患者數量、治療方法以及採用或不採用特定治療方法的原因。重點領域包括：

  • 醫療服務提供者狀況與病患群體：兒科病患群體、近視盛行率（5-17 歲）以及參與積極近視矯正計畫的病患比例。
  • 治療方案採納與臨床策略：角膜塑形術、近視控制軟性隱形眼鏡、眼鏡和低劑量阿托品在真實世界中的臨床應用，包括一線治療和聯合治療的趨勢。
  • 角膜塑形術的應用與經濟效益：處方鏡片及品牌、每位患者的年用量、定價及捆綁策略、患者平均自付費用、滿意度以及推廣應用的障礙。
  • 低劑量阿托品處方：患者數量和處方量、廠商定價和患者自付費用、依從性和推廣應用的障礙，以及FDA批准的無防腐劑配方上市後的預期變化。
  • 近視控制​​軟式隱形眼鏡：按品牌劃分的使用情況、治療持續時間、追蹤頻率、依從性挑戰以及對療效的認知。
  • 療效、依從性和障礙：醫療服務提供者評估的兒童和成人近視治療療效、依從性挑戰和推廣障礙。
  • 在研療法和市場發展：新興療法（包括阿托品釋放鏡片和重複低強度紅光療法 (RLRL)）的預期影響、定價和使用時間長度。
  • 技術與工作流程創新：對先進角膜塑形鏡驗配軟體的信心以及可能推動醫療服務提供者採用該軟體的因素。

研究方法：

Market Scope 於 2025 年 8 月至 9 月在美國開展了近視管理市場 (2025) 研究，旨在評估當前兒童近視管理實踐的現狀和新興市場趨勢。

在 Market-Scope.com 網站上自行註冊的眼科醫生和驗光師（包括普通眼科醫生和兒科眼科醫生）均受邀參與本次調查。我們於 2025 年 9 月 5 日發送了電子郵件邀請，並於 2025 年 9 月 26 日發送了最終提醒。

本次調查共收到 150 份完整且唯一的回覆。所有結果均以匿名化後的醫生報告數據的總結分析形式呈現，並根據每個問題的受訪者人數進行計算，因為不同類型醫生和執業領域的適用性有所不同。

我們未嘗試對受訪者群體以外的情況進行推論。問卷由 Market Scope 與贊助公司合作制定，所有資料均按照 Market Scope 的資料安全標準進行安全儲存和管理。

簡介目錄

Market Scope's "2025 Myopia Management Survey Report" delivers a comprehensive, provider-level view of how pediatric myopia is being managed in the United States today-examining patient volumes, treatment mix, economics, unmet needs, and how clinical behavior is likely to shift as new therapies reach the market.

Conducted in August and September 2025, the survey captures insights from 150 US-based optometrists and ophthalmologists, including comprehensive and pediatric specialists actively treating myopia. Respondents were drawn from Market Scope's self-registered provider community and reflect real-world clinical decision-makers with direct experience in myopia control.

The report provides a structured summary analysis of de-identified survey data, calculated at the respondent level and presented without market extrapolation to clearly show how providers are thinking, prescribing, pricing, and planning.

Contents:

The "2025 Myopia Management Survey Report" delivers granular insight into how many patients providers are seeing, how they are treated, and why certain therapies are-or are not-used. Key areas of coverage include:

  • Provider Landscape & Patient Volumes: Pediatric patient loads, myopia prevalence (ages 5-17), and the share of patients enrolled in active myopia control programs.
  • Treatment Adoption & Clinical Strategy: Real-world use of ortho-k, myopia control soft contact lenses, spectacles, and low-dose atropine, including first-line and combination therapy preferences.
  • Ortho-K Utilization & Economics: Lenses and brands prescribed, annual volumes per patient, pricing and bundling strategies, average patient costs, satisfaction, and adoption barriers.
  • Low-Dose Atropine Prescribing: Patient and bottle volumes, manufacturer and patient pricing, compliance and adoption barriers, and expected shifts with FDA-approved, preservative-free options.
  • Myopia Control Soft Contact Lenses: Brand usage, treatment duration, follow-up cadence, compliance challenges, and perceived effectiveness.
  • Effectiveness, Compliance & Barriers: Provider-rated effectiveness by modality, compliance challenges, and pediatric and adult adoption barriers across treatments.
  • Pipeline Therapies & Market Evolution: Expected impact, pricing, and duration of use for emerging options, including atropine-eluting lenses and repeated low-level red-light therapy (RLRL).
  • Technology & Workflow Innovation: Willingness to trust advanced ortho-k fitting software and the factors most likely to drive provider adoption.

Methodology:

Market Scope conducted the 2025 Myopia Management Survey in the United States during August and September 2025 to assess real-world pediatric myopia management practices and emerging market trends.

Ophthalmologists and optometrists-including comprehensive and pediatric specialists-who self-registered on Market-Scope.com were invited to participate. Email invitations were distributed on September 5, 2025, with a final reminder sent on September 26, 2025.

The survey yielded 150 complete, unique responses. All results are presented as a summary analysis of de-identified, provider-reported data and are calculated based on the number of respondents for each question, as applicability varied by provider type and treatment mix.

No extrapolation beyond the respondent base was performed. Survey questions were developed by Market Scope in collaboration with sponsoring companies, and all data are securely stored and maintained in accordance with Market Scope's data security standards.